PRESS RELEASE
Elevar Therapeutics
![Elevar Therapeutics]()
Elevar Therapeutics
Elevating Outcomes, Evolving Therapeutic Potential, Engaging with Purpose
Today we announced the landmark overall survival results from our Phase 3 CARES-310 trial in first-line #uHCC. The results will be presented at an in-person poster presentation on June 1 at #ASCO2024. Read more here: Elevar Therapeutics Reports Landmark Median Overall Survival of 23.8 Months in First-Line Treatment for Unresectable Hepatocellular Carcinoma #ElevarAtASCO
Rare disease science addict, humble servant to unmet patient needs
9 个月Congrats
National Life Sciences Business Development Leader at RSM US LLP, Board of Advisors
9 个月Great news! Longest median overall survival for any treatment in a global Phase 3 trial in uHCC. Amazing.
Executive Assistant Professional -Time Management l Event Planning l Calendaring l Meeting Scheduling l Complex Global Travel
9 个月Congratulations Elevar! That is such fantastic news! Keep up the great work.